Acceder

Publicaciones - FARMACOCINETICA CLINICA Y FARMACOTERAPIA APLICADA

Cargando...
Guzman-Laiz R, Iniesta-Navalon C, Rios-Saorin M, Anez-Castano R, Rentero-Redondo L, Nicolas-de Prado I, Gomez-Espin R, Urbieta Sanz E. Utility of tolerance assays for real-time management of infliximab infusion reactions. Rev Esp Enferm Dig. 2026 Jan 22. doi: 10.17235/reed.2026.11049/2024. Online ahead of print. PubMed PMID: 41569131.
AÑO: 2026; IF: 4.0
41569131
Guzman-Laiz R, Iniesta-Navalon C, Rios-Saorin M, Rentero-Redondo L, Garcia-Masegosa I, Anez-Castano R, Urbieta-Sanz E. Immunogenicity phenotypes and reversal of pharmacokinetic impact in anti-TNF-treated immune-mediated diseases: a real-world study. Int J Clin Pharm. 2026 Feb;48(1):246-256. doi: 10.1007/s11096-025-02043-6. Epub 2025 Nov 15. PubMed PMID: 41240271.
AÑO: 2026; IF: 3.2
41240271
Iniesta-Navalon C, Saorin MR, Neira-Torrecillas JM, Rentero-Redondo L, Garcia-Masegosa I, Gil-Almela J, Urbieta-Sanz E. External Evaluation of Population Pharmacokinetic Models of Ustekinumab in Patients with Inflammatory Bowel Disease. Ther Drug Monit. 2025 Apr 3. doi: 10.1097/FTD.0000000000001329. Online ahead of print. PubMed PMID: 40178486.
AÑO: 2025; IF: 2.4
40178486
Iniesta-Navalon C, Rentero-Redondo L, Gomez-Espin R, Rios Saorin M, Nicolas de Prado I, Gascon-Canovas JJ. Exploring infliximab serum level variability in inflammatory bowel disease: Comprehensive analysis of patient subgroups and treatment outcomes. Gastroenterol Hepatol. 2025 May 23:502472. doi: 10.1016/j.gastrohep.2025.502472. Online ahead of print. English, Spanish. PubMed PMID: 40414284.
AÑO: 2025; IF: 1.9
40414284
Solana-Altabella A, Iniesta-Navalon C, Chovi-Trull M, Rodriguez-Veiga R, Lopez-Nogueroles M, Martinez-Cuadron D, Gil-Candel M, Torres-Minana L, Acuna-Cruz E, Cano-Ferri I, Boluda B, Navarro-Vicente I, Lloret-Madrid P, Barragan E, Gil JV, Rodenas-Rovira M, Megias-Vericat JE, Labrador J, Peris-Ribera JE, Poveda-Andres JL, Montesinos P. Validation of pharmacokinetic model for quizartinib quantified by UPLC-MS/MS in patients with FLT3-ITD negative newly diagnosed acute myeloid leukemia. Eur J Clin Pharmacol. 2025 Aug 30. doi: 10.1007/s00228-025-03909-4. Online ahead of print. PubMed PMID: 40884550.
AÑO: 2025; IF: 2.7
40884550
Siguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

FARMACOCINETICA CLINICA Y FARMACOTERAPIA APLICADA